Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Mesothelioma × Data Collection × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Neoplasms 15 Papillomavirus Infections 9 Uterine Cervical Neoplasms 6 Pancreatic Neoplasms 5 Breast Neoplasms 5 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Neuroendocrine Tumors 4 Neoplasm Metastasis 4 Multiple Myeloma 3 Lymphoma 3 Autoimmune Diseases 3 Thyroid Diseases 2 Pancreatic Cyst 2 Neuroblastoma 2 Myasthenia Gravis 2 Mesothelioma, Malignant 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Leukemia, Hairy Cell 2 Leukemia 2 Hematologic Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 COVID-19 2 Abortion, Spontaneous 2 Wilms Tumor 1

Interventions

Pemetrexed 32 Cisplatin 27 pembrolizumab 18 Nivolumab 15 Carboplatin 13 Ipilimumab 11 Gemcitabine 9 Cyclophosphamide 7 durvalumab 6 fludarabine 5 Bevacizumab 5 Dexamethasone 4 tremelimumab 3 tazemetostat 3 olaparib 3 Vinorelbine 3 Radiotherapy, Intensity-Modulated 3 Paclitaxel 3 LMB-100 3 Imatinib Mesylate 3 Fluorouracil 3 sargramostim 2 niraparib 2 fludarabine phosphate 2 defactinib 2 budigalimab 2 belinostat 2 atezolizumab 2 anetumab ravtansine 2 Vorinostat 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05308966 2025-10-06

MESO-IMMUNE

Groupe Francais De Pneumo-Cancerologie

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡